Timing Matters: Sequential Pembrolizumab Plus Chemoradiation Outperforms Concurrent Approach in Locally Advanced Head and Neck Cancer

MedXY Editorial Team•Oct 1, 2025•Clinical Updates

Sequential administration of pembrolizumab after chemoradiation significantly improved 4-year locoregional control (LRC) compared to concurrent administration in locally advanced head and neck cancer.
Both treatment strategies met efficacy and safety benchmarks, but sequential therapy showed numerically better progression-free and overall survival.
Distinct immunosuppressive changes in the tumor microenvironment were observed based on the timing of pembrolizumab, potentially informing future immunotherapy strategies.
This randomized Phase II trial addresses a critical question regarding optimal integration of immunotherapy with standard chemoradiation in high-risk HNSCC.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Sequential administration of pembrolizumab after chemoradiation significantly improved 4-year locoregional control (LRC) compared to concurrent administration in locally advanced head and neck cancer.
Both treatment strategies met efficacy and safety benchmarks, but sequential therapy showed numerically better progression-free and overall survival.
Distinct immunosuppressive changes in the tumor microenvironment were observed based on the timing of pembrolizumab, potentially informing future immunotherapy strategies.
This randomized Phase II trial addresses a critical question regarding optimal integration of immunotherapy with standard chemoradiation in high-risk HNSCC.